Related Experiment Videos
Multiple sclerosis: clinical presentation, diagnosis and treatment
S A Brod1, J W Lindsey, J S Wolinsky
1University of Texas Health Science Center at Houston, USA.
American Family Physician
|September 15, 1996
Summary
New treatments for multiple sclerosis (MS) show promise. Interferon beta-1b, interferon beta-1a, and copolymer-1 may reduce relapses and central nervous system lesions in MS patients.
Area of Science:
- Neuroimmunology
- Neurology
Background:
- Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease.
- MS involves relapses, remissions, and progressive neurologic disability.
- It is believed to be a T cell-mediated autoimmune disorder.
Purpose of the Study:
- To evaluate the efficacy of new treatments for relapsing-remitting multiple sclerosis.
- To assess the impact of novel therapies on relapse rates and central nervous system lesion development.
Main Methods:
- Clinical trials were conducted to assess interferon beta-1b, interferon beta-1a, and copolymer-1.
- Outcomes measured included relapse rates and the development of new central nervous system lesions.
Main Results:
- Interferon beta-1b demonstrated a 30% decrease in relapses and reduced new CNS lesions.
- Interferon beta-1a showed a 31% reduction in relapse rate and fewer active lesions.
- Copolymer-1 (20 mg) reduced relapses by 21% with no significant side effects.
Conclusions:
- Novel treatments like interferons and copolymer-1 offer potential benefits for managing multiple sclerosis.
- These therapies show promise in reducing disease activity and alleviating clinical symptoms.
- Further research is warranted to fully understand the long-term impact of these treatments.